VYTORIN EZETIMIBE SIMVASTATIN 10/20 MG 14 TABS

Prevention of cardiovascular events: It is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), whether or not they have been previously treated with a statin. - Hypercholesterolemia: It is indicated as adjunctive treatment to diet in patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed hyperlipidemia when the use of a combination product is considered appropriate: patients not adequately controlled on a statin alone; patients already treated with a statin and ezetimibe. - Homozygous familial hypercholesterolemia (HoFH): It is indicated as a complementary treatment to diet in patients with HoFH. Patients may also receive complementary treatments (eg, low-density lipoprotein [LDL] apheresis).